Prevalence of metabolic syndrome among patients with Alzheimer disease: A systematic review and meta-analysis.
Mohammad Amouzad-Lichahi, Iliya Petkov, Aseel Smerat et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis examined the prevalence of metabolic syndrome (MetS) in patients with Alzheimer disease (AD). Among nine studies, the pooled prevalence of MetS in AD patients was found to be 46.7% (95% CI: 28.0%-65.8%). The analysis revealed significant heterogeneity among studies and no statistically significant association between AD and MetS.
Key findings
- The pooled prevalence of MetS among AD patients was 46.7% (95% CI: 28.0%-65.8%).
- Prevalence varied by continent: 26.1% in Asia, 52.8% in Europe, and 72.2% in North America.
- The odds ratio for the association between AD and MetS was 1.64 (95% CI: 0.75-3.57), not statistically significant.
- Glucose levels were significantly associated with MetS prevalence (β = 0.022; P = .021).
Why it matters
Understanding the prevalence of metabolic syndrome in Alzheimer disease patients is crucial for identifying potential comorbidities that may impact management and treatment strategies. This knowledge can guide clinicians in monitoring and addressing metabolic health in this population.
What to keep in mind
The study noted substantial heterogeneity among included studies, which may affect the reliability of the pooled prevalence estimate.